Skip to main content

Advertisement

SpringerLink
Log in

Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl

  • Original Article
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Introduction

Illicitly manufactured fentanyl (IMF) is responsible for a growing number of deaths. Some case series have suggested that IMF overdoses require significantly higher naloxone doses than heroin overdoses. Our objective was to determine if the naloxone dose required to treat an opioid overdose is associated with the finding of fentanyl, opiates, or both on urine drug screen (UDS).

Methods

A retrospective chart review was conducted at a single emergency department and its affiliated emergency medical services (EMS) agency. The charts of all patients who received naloxone through this EMS from 1/1/2017 to 6/15/2018 were reviewed. The study included patients diagnosed with a non-suicidal opioid overdose whose UDS was positive for opiates, fentanyl, or both. Data collected included demographics, vital signs, initial GCS, EMS and ED naloxone administrations, response to treatment, laboratory findings, and ED disposition. The fentanyl-only and fentanyl + opiate groups were compared to the opiate-only group using the stratified (by ED provider) variant of the Mann-Whitney U test.

Results

Eight hundred and thirty-seven charts were reviewed, and 121 subjects were included in the final analysis. The median age of included subjects was 38 years and 75% were male. In the naloxone dose analysis, neither the fentanyl-only (median 0.8 mg, IQR 0.4–1.6; p = 0.68) nor the fentanyl + opiate (median 0.8 mg, IQR 0.4–1.2; p = 0.56) groups differed from the opiate-only group (median 0.58 mg, IQR 0.4–1.6).

Conclusion

Our findings refute the notion that high potency synthetic opioids like illicitly manufactured fentanyl require increased doses of naloxone to successfully treat an overdose. There were no significant differences in the dose of naloxone required to treat opioid overdose patients with UDS evidence of exposure to fentanyl, opiates, or both. Further evaluation of naloxone stocking and dosing protocols is needed. 

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ahmad F, Rossen L, Spencer M, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2018.

  2. Kochanek K, Muprhy S, Xu J, Arias E. Mortality in the United States, 2016 National Center for Health Statistics; 2017.

  3. Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A, Wang Y, et al. Increases in fentanyl-related overdose deaths—Florida and Ohio, 2013-2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):844–9.

    Article  Google Scholar 

  4. CDC Health Alert Network. Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities. 2015. https://emergency.cdc.gov/han/han00384.asp. Accessed 10 Apr 2019.

  5. Rudd R, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52.

    Article  Google Scholar 

  6. Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2017: National Center for Health Statistics; 2018.

  7. Stogner JM. The potential threat of acetyl fentanyl: legal issues, contaminated heroin, and acetyl fentanyl disguised as other opioids. Ann Emerg Med. 2014;64(6):637–9.

    Article  Google Scholar 

  8. Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998;5(4):293–9.

    Article  CAS  Google Scholar 

  9. Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009;13(4):512–5.

    Article  Google Scholar 

  10. Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JS. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol. 2008;46(6):501–6.

    Article  CAS  Google Scholar 

  11. Somerville NJ, O'Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, et al. Characteristics of fentanyl overdose—Massachusetts, 2014-2016. MMWR Morb Mortal Wkly Rep. 2017;66(14):382–6.

    Article  Google Scholar 

  12. Scheuermeyer FX, DeWitt C, Christenson J, Grunau B, Kestler A, Grafstein E, et al. Safety of a brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann Emerg Med. 2018;72:1):1–8. e1.

    Article  Google Scholar 

  13. Cretikos MA, Bellomo R, Hillman K, Chen J, Finfer S, Flabouris A. Respiratory rate: the neglected vital sign. Med J Aust. 2008;188(11):657–9.

    Article  Google Scholar 

  14. Evans J, Hogg M, Lunn J, Rosen M. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br Med J. 1974;2(5919):589–91.

    Article  CAS  Google Scholar 

  15. McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study. Addiction. 2018;113(3):484–93.

    Article  Google Scholar 

  16. Food and Drug Administration. Prescribing information for naloxone nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf. Accessed 10 Apr 2019.

  17. Immunalysis Corporation. Fentanyl urine HEIA drug screening kit. https://immunalysis.com/wp-content/uploads/2016/10/Fentanyl_HEIA_MKT50368_2.pdf. Accessed 10 Apr 2019.

  18. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.

    Article  CAS  Google Scholar 

  19. Osterwalder JJ. Naloxone—for intoxications with intravenous heroin and heroin mixtures-harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol. 1996;34(4):409–16.

    Article  CAS  Google Scholar 

  20. Carroll JJ, Marshall BD, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. Int J Drug Policy. 2017;46:136–45.

    Article  Google Scholar 

  21. Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: exploring users’ perceptions of fentanyl-adulterated and-substituted ‘heroin’. Int J Drug Policy. 2017;46:146–55.

    Article  Google Scholar 

  22. National Institute on Drug Abuse. Opioid overdose reversal with naloxone (Narcan, Evzio). https://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxone-narcan-evzio. Accessed 10 Apr 2019.

  23. Harm Reduction Coalition. Guide to developing and managing overdose prevention and take-home naloxone projects. 2012.

  24. Strang J, Manning V, Mayet S, Best D, Titherington E, Santana L, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008;103(10):1648–57.

    Article  Google Scholar 

  25. Silverstein JH, Rieders MF, McMullin M, Schulman S, Zahl K. An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth Analg. 1993;76(3):618-21.

    Article  Google Scholar 

  26. Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg. 2000;55(6):323–33.

    Article  CAS  Google Scholar 

Download references

Funding

This work was unfunded.

Author information

Authors and Affiliations

  1. Georgia Poison Center, 50 Hurt Plaza SE, Suite 600, Atlanta, GA, 30303, USA

    Joseph Carpenter, Brian Patrick Murray, Sukhshant Atti & Brent Morgan

  2. Department of Emergency Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Joseph Carpenter, Tim P. Moran, Arthur Yancey & Brent Morgan

Authors
  1. Joseph Carpenter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian Patrick Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sukhshant Atti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tim P. Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arthur Yancey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brent Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Carpenter.

Ethics declarations

Conflicts of Interest

None.

Additional information

Supervising Editor: Michael Levine, MD

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

ESM 1

(PDF 62 kb)

ESM 2

(PDF 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carpenter, J., Murray, B.P., Atti, S. et al. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl. J. Med. Toxicol. 16, 41–48 (2020). https://doi.org/10.1007/s13181-019-00735-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-019-00735-w

Keywords

Search

Navigation